Latest Cutter Capital Management, LP Stock Portfolio
$229Million | No. of Holdings #21
Cutter Capital Management, LP Performance
2025 Q1-0.08%
YTD-0.08%
2024-1.96%
About Cutter Capital Management, LP and 13F Hedge Fund Stock Holdings
On 2025-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, Cutter Capital Management, LP reported an equity portfolio of $229.6 Millions as of 31 Mar, 2025. <br><br> The top stock holdings of Cutter Capital Management, LP are BMY, AMGN, BIIB. The fund has invested 7.8% of it's portfolio in BRISTOL-MYERS SQUIBB CO and 6.8% of portfolio in AMGEN INC. <br><br> The fund managers got completely rid off REGENERON PHARMACEUTICALS (REGN), JOHNSON & JOHNSON (JNJ) and ABBVIE INC (ABBV) stocks. They significantly reduced their stock positions in ROYALTY PHARMA PLC (RPRX), NEWAMSTERDAM PHARMA COMPANY (NAMS) and BRIDGEBIO PHARMA INC (BBIO). Cutter Capital Management, LP opened new stock positions in BRISTOL-MYERS SQUIBB CO (BMY), BIOGEN INC (BIIB) and ELI LILLY & CO (LLY). The fund showed a lot of confidence in some stocks as they added substantially to CENTESSA PHARMACEUTICALS PLC (CNTA), TARSUS PHARMACEUTICALS INC (TARS) and PERRIGO CO PLC (PRGO).
Cutter Capital Management, LP Equity Portfolio Value
Last Reported on: 15 May, 2025
$229Million
as of May 15, 2025Cutter Capital Management, LP Annual Return Estimates Vs S&P 500
Our best estimate is that Cutter Capital Management, LP made a return of -0.08% in the last quarter. In trailing 12 months, it's portfolio return was -0.84%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| bristol-myers squibb co | 17,992,000 |
| biogen inc | 15,531,300 |
| eli lilly & co | 14,866,400 |
| roivant sciences ltd | 13,117,000 |
| verona pharma plc | 10,158,400 |
| madrigal pharmaceuticals inc | 7,949,520 |
| summit therapeutics inc | 7,716,000 |
| halozyme therapeutics inc | 7,657,200 |
New stocks bought by Cutter Capital Management, LP
Additions
| Ticker | % Inc. |
|---|---|
| centessa pharmaceuticals plc | 184 |
| tarsus pharmaceuticals inc | 82.22 |
| perrigo co plc | 62.81 |
| teva pharmaceutical inds ltd | 37.09 |
| amgen inc | 31.27 |
Additions to existing portfolio by Cutter Capital Management, LP
Reductions
| Ticker | % Reduced |
|---|---|
| royalty pharma plc | -53.34 |
| newamsterdam pharma company | -34.41 |
| bridgebio pharma inc | -30.28 |
| agios pharmaceuticals inc | -21.97 |
| insmed inc | -11.62 |
| ultragenyx pharmaceutical in | -6.76 |
Cutter Capital Management, LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| viridian therapeutics inc | -12,051,700 |
| akero therapeutics inc | -6,398,600 |
| vera therapeutics inc | -8,994,910 |
| moderna inc | -8,212,050 |
| neumora therapeutics inc. | -1,590,000 |
| johnson & johnson | -20,474,100 |
| sarepta therapeutics inc | -15,108,300 |
| janux therapeutics inc | -6,424,800 |
Cutter Capital Management, LP got rid off the above stocks
Sector Distribution
Cutter Capital Management, LP has about 100% of it's holdings in Healthcare sector.
- Healthcare
| Sector | % |
|---|---|
| Healthcare | 100 |
Market Cap. Distribution
Cutter Capital Management, LP has about 44.3% of it's portfolio invested in the large-cap and mega-cap stocks.
- MID-CAP
- LARGE-CAP
- SMALL-CAP
- MEGA-CAP
- UNALLOCATED
| Category | % |
|---|---|
| MID-CAP | 40.7 |
| LARGE-CAP | 37.8 |
| SMALL-CAP | 13.1 |
| MEGA-CAP | 6.5 |
| UNALLOCATED | 2 |
Stocks belong to which Index?
About 63.3% of the stocks held by Cutter Capital Management, LP either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
- S&P 500
| Index | % |
|---|---|
| Others | 36.8 |
| RUSSELL 2000 | 35.4 |
| S&P 500 | 27.9 |
Cutter Capital Management, LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Cutter Capital Management, LP
Cutter Capital Management, LP has 21 stocks in it's portfolio. About 62.8% of the portfolio is in top 10 stocks. TEVA proved to be the most loss making stock for the portfolio. RPRX was the most profitable stock for Cutter Capital Management, LP last quarter.
$229.65MTotal Value
31.00Positions
15 May, 2025Last Reported
| Expand | Holdingsorted ascending | % Portfolio | Shares Held | $ Value | % Change |
|---|---|---|---|---|---|
 Abbvie Inc Abbvie IncABBV Cutter Capital Management, LP's holding in Abbvie Inc over time | 0% | 0.00 | $0.00 0% | 100%decreased 100 percentsold off | |
 Agios Pharmaceuticals Inc Cutter Capital Management, LP's holding in Agios Pharmaceuticals Inc over time | 3% | 235,350 | $6.90M 3% | 21.97%decreased 21.97 percentreduced | |
 Akero Therapeutics Inc Cutter Capital Management, LP's holding in Akero Therapeutics Inc over time | 0% | 0.00 | $0.00 0% | 100%decreased 100 percentsold off | |
| 6.78% | 50,000 | $15.58M 6.78% | 31.27%increased 31.27 percentadded | ||
 Bridgebio Pharma Inc Cutter Capital Management, LP's holding in Bridgebio Pharma Inc over time | 5.88% | 390,644 | $13.50M 5.88% | 30.28%decreased 30.28 percentreduced | |
 Biogen Inc Biogen IncBIIB Cutter Capital Management, LP's holding in Biogen Inc over time | 6.76% | 113,500 | $15.53M 6.76% | Newnew position | |
 Bristol-Myers Squibb Co Cutter Capital Management, LP's holding in Bristol-Myers Squibb Co over time | 7.84% | 295,000 | $17.99M 7.84% | Newnew position | |
 Centessa Pharmaceuticals Plc Cutter Capital Management, LP's holding in Centessa Pharmaceuticals Plc over time | 2.62% | 418,127 | $6.01M 2.62% | 184.29%increased 184.29 percentadded | |
 Cytokinetics Inc Cytokinetics IncCYTK Cutter Capital Management, LP's holding in Cytokinetics Inc over time | 3.06% | 175,000 | $7.03M 3.06% | Newnew position | |
 Halozyme Therapeutics Inc Cutter Capital Management, LP's holding in Halozyme Therapeutics Inc over time | 3.33% | 120,000 | $7.66M 3.33% | Newnew position | |
 Insmed Inc Insmed IncINSM Cutter Capital Management, LP's holding in Insmed Inc over time | 6.19% | 186,384 | $14.22M 6.19% | 11.62%decreased 11.62 percentreduced | |
 Janux Therapeutics Inc Cutter Capital Management, LP's holding in Janux Therapeutics Inc over time | 0% | 0.00 | $0.00 0% | 100%decreased 100 percentsold off | |
 Johnson & Johnson Cutter Capital Management, LP's holding in Johnson & Johnson over time | 0% | 0.00 | $0.00 0% | 100%decreased 100 percentsold off | |
 Eli Lilly & Co Cutter Capital Management, LP's holding in Eli Lilly & Co over time | 6.47% | 18,000 | $14.87M 6.47% | Newnew position | |
 Madrigal Pharmaceuticals Inc Cutter Capital Management, LP's holding in Madrigal Pharmaceuticals Inc over time | 3.46% | 24,000 | $7.95M 3.46% | Newnew position | |
 Moderna Inc Moderna IncMRNA Cutter Capital Management, LP's holding in Moderna Inc over time | 0% | 0.00 | $0.00 0% | 100%decreased 100 percentsold off | |
 NAMS Newamsterdam Pharma CompanyNewamsterdam Pharma CompanyNAMS | 1.97% | 221,152 | $4.53M 1.97% | 34.41%decreased 34.41 percentreduced | |
 Perrigo Co Plc Perrigo Co PlcPRGO Cutter Capital Management, LP's holding in Perrigo Co Plc over time | 5.86% | 479,517 | $13.45M 5.86% | 62.81%increased 62.81 percentadded | |
 Ultragenyx Pharmaceutical In Cutter Capital Management, LP's holding in Ultragenyx Pharmaceutical In over time | 5.98% | 379,303 | $13.73M 5.98% | 6.76%decreased 6.76 percentreduced | |
 Arcus Biosciences Inc Cutter Capital Management, LP's holding in Arcus Biosciences Inc over time | 2.5% | 731,818 | $5.74M 2.5% | Newnew position | |
